Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: Measurements with stable isotopes  by de Sain-van der Velden, Monique G.M. et al.
Proportionate increase of fibrinogen and albumin synthesis in
nephrotic patients: Measurements with stable isotopes
MONIQUE G.M. DE SAIN-VAN DER VELDEN, GEORGE A. KAYSEN, KEES DE MEER, FRANS STELLAARD,
HIERONYMUS A.M. VOORBIJ, DIRK-JAN REIJNGOUD, TON J. RABELINK, and HEIN A. KOOMANS
Departments of Nephrology and Hypertension, and Clinical Chemistry, University Hospital Utrecht, Utrecht, The Netherlands;
Department of Medicine, Division of Nephrology, University of California at Davis, Davis, and Department of Veterans Affairs Northern
California Health Care System, Pleasant Hill, California, USA; Department of Gastroenterology, Wilhelmina Childrens Hospital, Utrecht,
and Department of Nutrition and Metabolism, and Department of Metabolic Disorders, University Hospital Groningen, Groningen, The
Netherlands
Proportionate increase of fibrinogen and albumin synthesis in ne-
phrotic patients: Measurements with stable isotopes. Hyperfibrinogen-
emia is a common feature of the nephrotic syndrome, and contributes to
increased tendency for thrombosis and atherosclerosis. Its genesis is not
certain, but the increase in liver fibrinogen mRNA in nephrotic rats
indicates increased synthesis. Data in humans are scarce. We presently
compared synthesis rates of fibrinogen and albumin in nephrotic adults
(N 5 7; plasma albumin 22.3 6 0.7 g/liter, proteinuria 12 g/day) and
healthy control subjects (N 5 8) using a primed/continuous infusion of the
stable isotope L-[1-13C]valine for six hours. Absolute synthesis rate (ASR)
of fibrinogen was 31 6 3 mg/kg/day in nephrotic subjects and 21 6 1
mg/kg/day in control subjects (P , 0.05), and positively correlated with
plasma fibrinogen (P 5 0.0317). The plasma fibrinogen pool was dispro-
portionately increased in the nephrotic patients (271 6 30 mg/kg)
compared to the controls (126 6 8 mg/kg), suggesting decreased fractional
catabolic rate as well. The ASR of albumin was increased from 71 6 4
mg/kg/day in the controls to 160 6 19 mg/kg/day in the patients (P ,
0.0001), and strongly correlated with the ASR of fibrinogen (P 5 0.0046).
Plasma a2-macroglobulin was also elevated and correlated with the
albumin synthesis rate, whereas plasma serum amyloid A and C-reactive
protein were not elevated. These data suggest that in nephrotic patients
the increased albumin synthesis is associated with an increase in synthesis
of a specific and coordinated group of proteins, among which is fibrinogen.
The nephrotic syndrome is characterized by proteinuria (. 3.5
g/day) and a reduction in the concentration of albumin and other
proteins of intermediate molecular weight [1]. In contrast, the
concentration of lipoproteins [2–7] and several proteins of high
molecular weight such as fibrinogen and macroglobulins are
increased [1, 8–9]. Part of the reason for this difference is that
albumin, transferrin and IgG pass through the damaged glomer-
ulus [1] while large proteins, including IgM, a1- and a2-macro-
globulins, fibrinogen, factor XIII, fibronectin and larger lipopro-
teins, do not pass through it to any significant extent [8–11].
The concentration of proteins in plasma may be increased
either as a consequence of an increased synthesis, a decreased
catabolic rate, or both. While the rates of synthesis of many
plasma proteins are increased in the nephrotic syndrome [8,
11–18], this is not true for all proteins [13, 18, 19]. Plasma
fibrinogen concentration is increased, and evidence from ne-
phrotic rats suggests that an increased rate of synthesis of this
protein may contribute to its increased plasma concentration.
mRNAs coding for fibrinogen and albumin in the liver are
increased in rats with the nephrotic syndrome [8, 13]. Further-
more, the rate of transcription of their genes is also increased in
livers of nephrotic rats [8], suggesting coordinate increases in the
synthesis of these two proteins in the nephrotic syndrome. It is,
however, not certain whether these results can be translated to
humans, since no direct assessments have been done.
The aim of the present study was to simultaneously measure the
synthesis rates of fibrinogen and albumin in patients with the
nephrotic syndrome and to compare them with measurements in
a control group. For this purpose, we used a primed/continuous
infusion of the stable isotope labeled valine, and measured its
enrichment in the purified proteins using gas chromatography
combustion isotope ratio mass spectrometry (GC/C/IRMS). Be-
sides the relationship between fibrinogen and albumin synthesis
and their respective plasma protein levels, we also measured the
concentration of three other acute phase proteins [a2-macroglob-
ulin, C-reactive protein (CRP) and serum amyloid A (SAA)],
since it was suggested that a group of proteins is up-regulated
coordinately in the nephrotic syndrome [8].
METHODS
Subjects
Seven patients (five males) with a nephrotic syndrome (protein-
uria . 3.5 g/day and plasma albumin concentration , 30 g/liter)
were studied. Their mean age was 50 years (range 31 to 63) and
mean body wt 83.8 kg (range 68.6 to 92.0). All patients had a
stable nephrotic syndrome of at least three months duration
(mean duration 19 months, range 3 to 54 months). Six patients
had membranous glomerulopathy and one had minimal change
disease (indicated by biopsy). Patients were prescribed a diet
containing 0.8 g protein/kg body wt/day and 100 mmol sodium/
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day. Besides diuretics, they used no medication, or medication
was stopped at least two weeks before the infusion study (see
below). Control studies were done in eight healthy subjects (four
males), mean age 32 years (range 25 to 41), mean weight 76.7 kg
(range 64.1 to 103.4) under similar dietary conditions. One day
before the infusion study, the subjects collected 24-hour urine
specimens that were analyzed for urea, creatinine, protein and
albumin.
Patients and volunteers agreed to participate after informed
consent in accordance with the Helsinki Declaration of Human
Rights. The study was approved by the Institutional Ethical
Committee for studies in Humans.
Materials
L-[1-13C] valine (isotope mole fraction . 0.99; MassTrace,
Woburn, MA, USA) was dissolved in sterile 0.9% saline and
sterilized through a 0.22 mm filter. All chemicals were obtained
from Riedel de Hae¨n (Seelze, Germany) unless otherwise indi-
cated.
Infusion protocol
The subjects came to the research unit in the morning after a 12
hour fast. Bilateral cubital arm veins were cannulated for blood
sampling and for injection of Evans blue and the labeled valine.
No food was given during the tracer infusions, and subjects were
only allowed to drink water. After the subjects were in supine
position for at least 30 minutes, baseline blood samples were
taken and an i.v. dose of evans blue was given. After 10, 15, 20, 30,
45 and 60 minutes, samples were taken to measure the Evans blue
distribution volume, an index for plasma volume [20]. At t 5 0, a
priming dose of 15 mmol/kg L-[1-13C] valine was administered
intravenously over two minutes, followed by a continuous infusion
of 15 mmol/kg/hr L-[1-13C] valine during six hours. Blood samples
were collected into heparine-containing tubes and into citrate
containing tubes. Samples were taken from the contralateral arm
at indicated intervals (Fig. 1) and kept on ice (maximum 1 hr)
until plasma was separated by centrifugation (20 min, 3000 3 g,
4°C). Plasma samples were stored at 220°C until further prepa-
ration. During the infusion period, 11 samples were drawn for
determination of the labeled/unlabeled ratio of valine (tracer/
tracee ratio) in plasma and for the determination of the tracer/
tracee ratio in albumin and fibrinogen.
Biochemical analysis
Isolation of plasma amino acids from plasma and proteins. Free
amino acids in plasma were isolated from 750 ml heparin plasma
by deproteinization with 750 ml 20% trichloric acetic acid (TCA).
After centrifugation (10 min, 2000 3 g, room temperature) the
supernatant was directly applied to cation-exchange columns as
described below.
Albumin was isolated from plasma based on differential solu-
bility in absolute ethanol from TCA-precipitated proteins accord-
ing to the method of Korner and Debro [21]. Briefly, 0.5 ml
heparin plasma was deproteinized with 0.5 ml 20% TCA. After
centrifugation (10 min, 2000 3 g, room temperature), the pellet
was redissolved in 1 ml ethanol. After a second centrifugation, an
aliquote of the supernatant was used to monitor protein purity
and identification, using a 4 to 15% sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) gradient and
visualization by silver staining. Electrophoretically obtained bands
Fig. 1. Study protocol. Studies were performed
after the subjects had fasted for 12 hours. After
at least 30 minutes of recumbency, an
intravenous dose of Evans blue was given (t 5
2309). At t 5 0, a priming dose, directly
followed by a continuous infusion of L-[1-13C]
valine during 3609 was given. Symbols (* and
#) indicate blood sampling points for
determination of plasma volume and protein
synthesis, respectively.
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were compared with commercially obtained human albumin
(Behringwerke AG, Marburg, Germany). The purified albumin
exhibited as a single band corresponding to human albumin (not
shown). For quantification of albumin a Lowry method [22] was
used. Recovery of the isolation procedure was about 80%. To
remove free amino acids, a second aliquot of the ethanolic protein
solution containing 300 mg protein was evaporated under N2 at
45°C until dry. The residue was redissolved in 1 ml 0.3 M NaOH
at 37°C for 30 minutes. The albumin was reprecipitated with 1 ml
2 M HClO4 and subsequently with 1 ml 0.2 M HClO4 at 4°C before
hydrolysis.
Fibrinogen was purified from citrate plasma based on the
method of Vila et al [23]. Briefly, 0.5 ml plasma was added to 0.5
ml 80 g/liter polyethylene glycol 6000 (Merck, Darmstadt, Ger-
many). The mixture was placed on ice and gently shaken for 10
minutes. After centrifugation (10 min, 1800 3 g at 4°C) the
precipitate was redissolved in 1 ml phosphate buffer (0.01 M
Na2HPO4; BDH Chemicals Ltd, Poole, UK), 0.15 M NaCl, pH
7.4) and subsequently precipitated with 0.5 ml 2 M acetic-acid-
acetate buffer (pH 4.6). This mixture was again placed on ice for
30 minutes and gently shaken. After centrifugation the precipitate
was redissolved in 1 ml phosphate buffer (0.036 M Na2HPO4, pH
7.8, 200,000 U/liter aprotinin; Sigma Chemical, St. Louis, MO,
USA), and precipitated with 330 ml (NH4)2SO4 (4 mol/liter).
After centrifugation the pellet was redissolved in 1 ml phosphate
buffer (0.018 M Na2HPO4, 200,000 U/liter aprotinin, pH 7.8). A
part of the isolated fibrinogen was used to monitor purity and
identification using the same gel system as described for albumin.
Electrophoretically obtained bands were compared with commer-
cially obtained human fibrinogen (American Diagnostica Inc.,
Greenwich, CT, USA). Purified fibrinogen showed two electro-
phoretic bands, corresponding to the high and low molecular
weight form of fibrinogen (Fg1 5 340,000 Da and Fg2 5 320,000
Da). To verify the purity of fibrinogen we also reduced the
isolated fibrinogen. Samples were prepared by mixing 10 ml
purified fibrinogen with 40 ml of a reducing buffer containing 5%
SDS, 10% b-mercaptoethanol, 5% glycerol, and 0.2% bromophe-
nol blue and heating the mixture for five minutes at 100°C. The
reduced firinogen showed three electrophoretic bands with a
molecular weight of 67,000, 58,000 and 47,000 Da that can be
assigned to fibrinogen Aa, Bb and g chains. For quantification of
the fibrinogen a Lowry method [22] was used. Recovery of this
isolation procedure was about 80%. Subsequently, an aliquot of
the solution containing 300 mg of the fibrinogen was precipitated
by adding 1 ml 2 M HClO4. After centrifugation the precipitate
was used for hydrolysis.
Hydrolysis of both albumin and fibrinogen was done in 0.5 ml 6
N HCl for 24 hours at 110°C in sealed tubes [24]. The hydrolysates
and the supernatant after deproteinization of plasma were applied
to columns containing 2 ml of the cation-exchange resin, AG
50W-X8 (200 to 400 mesh), H1 form (Bio-Rad Laboratories,
Richmond, CA, USA), that had been prewashed with aqua-dest.
After washing with 10 ml of aqua-dest, the aminoacids were
eluted with 6 ml of 6 N NH4OH. The eluate was dried at 45°C
under N2 and the dried samples were kept at 4°C until derivati-
zation.
Determination of 13C-valine enrichment. The N(O,S)-methoxy-
carbonyl methyl esters of the isolated amino acids were prepared
according to the method of Husˇek [25]. For each series of analyses
a standard curve was used, prepared by disolving weighted
amounts of L-[1-13C] valine (infused tracer) and commercially
available L-valine in aqua-dest. Two standard curves were made,
one ranging between 0 and 0.25 tracer/tracee molar ratio and one
ranging between 0 and 0.025 tracer/tracee molar ratio. The
solutions were divided into aliquots and dried under a stream of
nitrogen and stored at 4°C until derivatization. The N(O,S)-
methoxycarbonyl methyl ester derivative of plasma-free aminoac-
ids was analyzed by GC/MS on a Hewlett-Packard HP 5890 type
II gas chromatograph interfaced to a JEOL JMS AX 505 mass
spectrometer (JEOL, Tokyo, Japan). Separation of derivatized
L-valine from other derivatized amino acids was achieved on a CP
Sil 19CB capillary column (Chrompack, Middelburg, the Nether-
lands). The column effluent was ionized by chemical ionization
with NH3, and resulting positively charged fragments were mon-
itored at m/z 190 and m/z 191. Each sample was analyzed in
triplicate (CV , 5%).
Aminoacids isolated from hydrolysates of fibrinogen and albu-
min were analyzed as their N(O,S)-methoxycarbonyl methyl ester
derivative by GC/C/IRMS on a Varian 3400 gas chromatograph,
equipped with a CuO combustion oven and interfaced to a
DELTA S isotope ratio mass spectrometer (Finnigan-MAT,
Bremen, Germany). Baseline separation of derivatized L-valine
from other derivatized amino acids, essential in this method, was
achieved on a CP Sil 19CB capillary column. The column effluent
was combusted and the resulting CO2 was monitored at m/z 44
and 45. This GC/C/IRMS method resembles a comparable GC/
C/IRMS method published by Yarasheki et al [26] that was
developed for the N-acetyl n-propyl ester of leucine.
Pre-infusion measurements. Pre-infusion plasma concentrations
of urea, creatinine, and albumin were measured with standard
laboratory methods on a Ektachem 950 (Johnson & Johnson,
Clinical Diagnostics, NY, USA). The measurement of albumin
was based on the broomcresol green method. C-reactive pro-
tein (CRP), urinary urea, urinary creatinine proteinuria and
albuminuria were measured with standard laboratory methods on
a Hitachi-911 (Boehringer, Mannheim, Germany). The colloid
osmotic pressure (COP) was measured using a 4400 colloid
osmometer (Wescor Inc., Logan, UT, USA). Fibrinogen was
measured using the Von Clauss method [27]. Serum amyloid A
(SAA) was measured using an ELISA (Hemagen Diagnostics,
Waltham, MA, USA) and a2-macroglobulin was measured using
a routine nephelometric method (Behringwerke AG, Marburg,
Germany).
Calculations and statistics
The mass spectrometry intensity ratios, either at m/z 191 and
m/z 190 for the GC/MS measurements or at m/z 45 and m/z 44 for
the GC/C/IRMS measurements, were converted to tracer/tracee
molar ratios by means of the appropiate calibration curves
depicting the relevant intensity ratio as a function of the molar
ratio of weighed amounts of L-[1-13C] valine/L-valine. For the
GC/MS measurements the calibration curve ranged from 0 to 0.25
tracer/tracee molar ratio and for the GC/C/IRMS measurements
the calibration curve ranged from 0 to 0.025 tracer/tracee molar
ratio was used. The fractional synthesis rate (FSR) of albumin and
fibrinogen were calculated from the tracer/tracee data [28] ac-
cording the formula and guidelines discussed by Foster et al [29]
and Parhofer et al [30]: the data were fitted to A(t) 5 Ap [1 2
e2k(t2d)], where A(t) is the tracer/tracee ratio of valine at time t
(in hours), Ap is the steady-state plasma tracer/tracee ratio of
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valine, d is a delay time and k represents the FSR of the protein.
Calculations were done using SPSS software. The absolute syn-
thesis rate (ASR), which is the amount of protein synthesized per
day, was calculated as the product of the FSR and the plasma pool
(plasma volume 3 plasma concentration). To adjust for different
body weights (wt), these quantities are expressed per kg body wt.
The significance of differences was assessed by Student’s t-test.
Data are expressed as means 6 SEM and means of the difference
with 95% confidence intervals.
RESULTS
Baseline data
The plasma values of urea, creatinine, albumin, COP, fibrino-
gen, a2-macroglobulin and SAA of patients and controls are
shown in Table 1. Judged from plasma urea and creatinine, the
patients had mildly disturbed renal function. Plasma albumin and
COP were decreased, plasma fibrinogen and a2-macroglobulin
were about twice normal, whereas plasma SAA was normal.
C-reactive protein (CRP), an index of inflammation, was also in
the normal range (, 5 mg/liter) in both patients and controls.
Twenty-four-hour urinary collections showed that the nephrotic
patients displayed considerable proteinuria. Urine urea excretion,
as an index of protein intake, was not significantly different from
that in the control subjects. Plasma volume was also comparable.
Synthesis rate of fibrinogen and albumin in patients and
control subjects
The absolute synthesis rate (ASR) of fibrinogen was signifi-
cantly increased by about 50% in the patients compared to the
control subjects (Table 2). By inference, assuming steady state and
no external loss, fibrinogen catabolism was increased to the same
extent. However, the fibrinogen pool was increased disproportion-
ately. Therefore, the FSR of fibrinogen (and, by inference, its
fractional catabolic rate, FCR) was significantly decreased to
11.6 6 0.9%/day, compared to measurements in the control
subjects, 16.9 6 0.6%/day (P , 0.0001). The ASR of albumin was
twice that measured in control subjects. Different from the FSR of
fibrinogen, the FSR of albumin was greatly increased.
Correlations
Considering the data in controls and patients together, several
correlations were found. Importantly, the ASR of albumin corre-
lated with the ASR of fibrinogen (r2 5 0.79, P , 0.0001; Fig. 2).
Further, the ASR of fibrinogen correlated directly with plasma
concentration of fibrinogen (r2 5 0.70, P 5 0.0001; Fig. 3) and
negatively with plasma albumin (r2 5 0.39, P 5 0.0127) and COP
(r2 5 0.40, P 5 0.0115). The ASR of albumin correlated nega-
tively with plasma albumin concentration (r2 5 0.56, P 5 0.0014;
Fig. 4), and COP (r2 5 0.59, P 5 0.0008) and positively with
plasma fibrinogen concentration (r2 5 0.75, P , 0.0001) and
plasma a2-macroglobulin concentration (r
2 5 0.82, P , 0.0001),
but not with other acute phase proteins, SAA and CRP.
Given the large variation in ASR of albumin and fibrinogen in
the patient group (Fig. 2), we also evaluated correlations within
this group separately. Again, there was a strong correlation
between the ASR of albumin and the ASR of fibrinogen (r2 5
0.83, P 5 0.0046), and positive correlations were found between
the ASR of fibrinogen and plasma fibrinogen concentration (r2 5
0.64, P 5 0.0317). Within this group, no correlations were found
between the ASR of albumin and plasma albumin concentration,
COP, plasma fibrinogen concentration, plasma a2-macroglobulin
concentration, and proteinuria. More importantly, there was a
wide range in ASR of albumin in the patient group despite a




(N 5 8) P value
Plasma urea mmol/liter 7.7 6 1.3 (4.1–14.3) 3.7 6 0.3 (2.4–4.8) ,0.01
Plasma creatinine mmol/liter 121 6 12 (89–164) 75 6 4 (60–89) ,0.01
Plasma albumin g/liter 22.3 6 0.7 (19.9–24.4) 37.3 6 0.8 (33.7–40.2) ,0.0001
Plasma COP mm Hg 11.2 6 0.4 (9.5–12.3) 24.6 6 0.5 (22.4–26.2) ,0.0001
Plasma fibrinogen g/liter 6.5 6 0.5 (4–8.04) 3.1 6 0.2 (2.2–4.1) ,0.0001
Plasma a2-macroglobulin g/liter 3.69 6 0.51 (2.0–6.1) 1.61 6 0.09 (1.3–2.0) ,0.0001
Plasma SAA mg/liter 9.7 6 2.8 (3.0–27.0) 7.1 6 1.4 (1–11.5) NS
Plasma volume ml/kg 40 6 2 (34–46) 40 6 2 (32–46) NS
Proteinuria mg/kg/day 139 6 22 (80–240) ,1.5 ,0.0001
Albuminuria mg/kg/day 111 6 16 (53–182) ND ,0.0001
Creatinine clearance ml/min 86 6 7 (62–109) 131 6 11 (84–177) ,0.01
Urinary urea mmol/kg/day 3.4 6 0.3 (1.7–4.6) 4.3 6 0.3 (2.8–5.7) NS
Values are expressed as mean 6 SEM (range). Abbreviations are: ND, not done, NS, not significant; COP, colloid osmotic pressure; SAA, serum
amyloid A. P values were determined by t-test.
Table 2. Fibrinogen pool and fractional synthesis rate (FSR) and





(N 5 8) P value
Fibrinogen
pool mg/kg
271 6 30 (136–370) 126 6 8 (90–157) ,0.0001
Fibrinogen
FSR %/day
11.6 6 0.9 (8.9–14.7) 16.9 6 0.6 (13.9–18.5) ,0.0001
Fibrinogen
ASR mg/kg/day
31 6 3 (23–45) 21 6 1 (14–27) ,0.05
Albumin FSR
%/day
17.1 6 1.3 (12.7–22.0) 4.8 6 0.3 (3.3–6.4) ,0.0001
Albumin ASR
mg/kg/day
160 6 19 (107–241) 71 6 4 (53–88) ,0.0001
Values are expressed as mean 6 SEM (range).
P values were determined by t-test.
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relatively narrow range in plasma albumin concentrations (Fig. 4).
Plasma CRP and SAA concentrations were normal in the patient
group and did not correlate with the ASR of albumin.
DISCUSSION
The present study clearly demonstrates that whereas plasma
albumin is reduced and plasma fibrinogen is increased in the
nephrotic syndrome, the synthesis rate of both proteins is in-
creased and interrelated. This implies that in the nephrotic
syndrome synthesis of albumin and fibrinogen is probably regu-
lated by a common signal. We also found that in the nephrotic
subjects the plasma fibrinogen concentration is directly correlated
to the absolute synthesis rate of fibrinogen. The FSR of fibrinogen
and thus the fractional catabolic rate (FCR) (assuming steady
state and no external loss) is decreased compared to controls,
suggesting that a reduced FCR of fibrinogen also contributes to
the increased plasma levels of this protein.
In this study, albumin and fibrinogen synthesis were determined
by using a primed/continuous infusion model and GC/C/IRMS as
the detection technique. There are only few reports on measure-
ments of albumin and fibrinogen synthesis rates in nephrotic
patients. Some investigators used decay curves of I-labeled pro-
teins [31, 32]. However, using decay curves is not ideal, since
I-labeled protein may be denaturated and the labeling itself may
contribute to modification of the protein. Measurement of syn-
thesis with use of a flooding dose [17] also has limitations, since
administration of large dosages of aminoacid may directly stimu-
late protein synthesis [33]. We therefore used a primed/continu-
ous infusion model. Instead of the commonly used leucine, we
used L-[1-13C] valine as the stable isotope. Valine does not
stimulate insulin, a well known factor stimulator of protein
synthesis in vivo [34, 35]. Other advantages of valine are that it is
the most soluble essential aminoacid, and that protein valine
content is generally high. Separation of valine from the other
aminoacids by gas chromatography is technically feasable,
whereas leucine and isoleucine cannot be easily separated. The
presently calculated FSR of fibrinogen (16.9 6 0.6%/day) and
FSR of albumin (4.8 6 0.3%/day) in normal subjects are lower
than generally published [34–43]. However, this is an artifact
since we used the tracer/tracee ratio of valine in plasma per se,
whereas others made a correction for the presumed lower ratios in
the cell compartment [33, 44].
To our knowledge, this is the first study reporting direct
measurement of fibrinogen synthesis in nephrotic patients.
Takeda and Chen [31] evaluated fibrinogen decay with 131I-
labeled fibrinogen in patients with the nephrotic syndrome. Since
Fig. 2. Relationship between the absolute synthesis rate (ASR) of fibrin-
ogen (mg/kg/day) and the ASR of albumin (mg/kg/day) for nephrotic
patients (F, N 5 7) and controls (E, N 5 8). The 95% confidence limits
of the entire group are shown on either side of the regression line. r2 5
0.79, P , 0.0001 (N 5 15).
Fig. 3. Relationship between plasma fibrinogen concentration (g/liter)
and the absolute synthesis rate (ASR) of fibrinogen (mg/kg/day). The 95%
confidence limits of the whole group are shown on either side of the
regression line. r2 5 0.70, P 5 0.0001 (N 5 15). Symbols are: (E) controls,
N 5 8; (F) patients, N 5 7.
Fig. 4. Absolute synthesis rate (ASR) of albumin (mg/kg/day) and its
plasma concentration in both controls (E N 5 8) and patients (F, N 5 7).
The error bars indicate 6 1 SD.
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the catabolic rate was increased, they supposed that the increase
in plasma fibrinogen must be due to an increased synthesis. The
present data firmly establish that plasma fibrinogen is increased
due to increased synthesis of fibrinogen. Since the relatively large
fibrinogen molecule is not filtered in the diseased glomerulus in
the nephrotic syndrome, there is no urinary loss of this protein
[11]. This makes it likely that fibrinogen catabolism is increased to
the same extent. Increased fibrinogen catabolism is compatible
with increased fibrinogen use in the nephrotic syndrome, for
which our data thus give indirect support. Interestingly, the FSR
of fibrinogen in this study was lower than in normal subjects. This
implies that the increase in the fibrinogen pool in nephrosis
cannot be fully explained by increased synthesis of fibrinogen.
Assuming that fractional synthesis and catabolism of fibrinogen
are in equilibrium, our data suggest that a decrease in fractional
fibrinogen catabolism also contributes to the hyperfibrinogenemia
of the nephrotic syndrome.
The observed increase in albumin synthesis in this patient group
is in agreement with findings in both patients [14, 17, 32] and
animals [15, 16, 45–47] with the nephrotic syndrome. Our obser-
vation that there is no relationship between albumin synthesis rate
and plasma albumin concentration in the patient group is similar
to what has been found by others [14, 17, 32]. However, a wide
range in (elevated) synthesis rates of albumin was found, despite
about similarly (decreased) plasma albumin concentrations. This
suggests that: (1) the net albumin loss contributed variably to the
fall in plasma albumin, even though the resulting plasma albumin
concentrations were similar; (2) albumin synthesis was increased
to its maximal level in each patient, and this homeostatic mech-
anism failed to normalize albumin plasma concentrations, even
though the extravascular albumin pool and thus the effective
albumin distribution are strongly decreased [32]; and (3) other
factors besides plasma albumin or COP influence the albumin
synthesis rate in nephrotic syndrome [17, 48]. We did not find a
relationship between proteinuria and albumin synthesis rate in the
nephrotic patients. On the other hand, a positive correlation
between proteinuria and the albumin synthesis rate has been
found in both nephrotic humans [49] and rats [15] by estimation of
albumin synthesis from 125I albumin disappearance. Since the
latter measurements were made at steady state over many days we
have to consider that the presently used method, which measures
synthesis for only six hours, does not take into account possible
diurnal variations.
An important conclusion that we can draw independently of any
possible disturbing affect of diurnal variations in synthesis rates is
that in the nephrotic syndrome the synthesis of fibrinogen and
albumin are increased proportionally. This is in contrast with the
increased fibrinogen synthesis in type I diabetes mellitus, which
has been found to vary inversely with that of albumin [35]. In the
case of fibrinogen, the increased synthesis rate is not a response to
a changed plasma level, as might be hypothesized for albumin, but
instead increased plasma fibrinogen concentrations are a conse-
quence of the increased synthesis. That plasma a2-macroglobulin
concentrations are also increased and correlate with the ASR of
albumin suggests that synthesis of this protein may also be
increased, and reflects a more global change in the pattern of
protein synthesis and secretion by the liver in the neprotic
syndrome. With regard to increased synthesis rates of both
albumin and fibrinogen, this change represents a reversal of the
relationship between the synthesis rate of these two proteins
(which is usually reciprocal and not proportional [35]). Appar-
ently, the nephrotic syndrome is an instance in which syntheses of
both a positive and a negative acute phase protein are increased
in concert.
Neither CRP (115 to 140 kDa) nor SAA (220 to 235 kDa) levels
were increased in the nephrotic patients. While it might be
possible that, like albumin, their synthesis rates are increased but
fail to replace urinary losses, we feel this explanation to be
unlikely. Serum amyloid A (SAA) does not circulate in its free
form, but is tightly bound to high density lipoprotein (HDL) [50].
While small amounts of HDL are lost in the urine in the nephrotic
syndrome [51], this most likeley represents reduction in renal
processing of filtered apo A-I and not net renal filtration and loss
of HDL [52]. Thus, the opportunity for increased renal losses of
SAA is not great. Second, unlike either albumin or fibrinogen, the
concentrations of both of these proteins are capable of increasing
by several orders of magnitude when synthesis is stimulated [53].
Therefore, normal levels of SAA and CRP in nephrotic patients
most likely reflect unchanged hepatic secretion rates. Based on
these considerations, we speculate that in the nephrotic syndrome
hepatic secretion of a specific cohort of proteins is stimulated,
probably by a similar signal.
Some caution is required concerning the younger age in the
control subjects of our study, and the possible effects of age on
protein synthesis. As regards albumin synthesis, it has been shown
in a study using stable isotopes that, whereas the serum albumin
diminished slightly with age, FSR and ASR did not differ between
young adults and elderly subjects [54]. Plasma levels of fibrinogen
are related to age in adults, and show an increase of 3 to 10%/10
years [55–56]. Whether this is due to an increased synthesis or
decreased catabolism is not known. Nonetheless, it is unlikely that
the observed 50% increase in fibrinogen synthesis and doubling of
plasma fibrinogen in the nephrotic subjects reflect a physiological
age-related synthesis increase.
Plasma fibrinogen concentration in the nephrotic syndrome
draws much attention since epidemiological studies have shown
that a high plasma fibrinogen concentration is an independent risk
factor for atherosclerotic disease [57–61] and a predictor of
mortality in patients with coronary heart disease [62]. Elevation of
the plasma fibrinogen level is a consistent and significant abnor-
mality observed in patients with the nephrotic syndrome [63–65]
and these increased concentrations are associated with hyperco-
agulability, hyperviscosity and increased platelet aggregation [66].
In addition, increased plasma fibrinogen concentrations may
contribute to the progression of renal disease [9]. There are only
a few drugs successful in decreasing plasma fibrinogen [67–68],
and no data are yet available on whether such drugs are beneficial
in the nephrotic syndrome. Insight in the signal that causes
hyperfibrinogenemia may add to further leads for development of
rational therapy. Two clinically important consequences arise
from our observations. First, finding a relationship between the
ASR of fibrinogen and albumin in patients with the nephrotic
syndrome may be relevant for interventions that will augment
albumin synthesis. For example, increased dietary protein intake,
which may augment the albumin synthesis rate in the nephrotic
patient [16], may also increase fibrinogen synthesis and therefore
the plasma fibrinogen concentration. Thus, strategies aimed at
increasing the albumin synthesis rate may have an unfavorable
side effect compared to strategies aimed at reducing the defect in
glomerular permselectivity. Second, our data suggest that plasma
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fibrinogen may be a better marker for albumin synthesis (and thus
total albumin loss) than proteinuria. Whether that also holds true
for mild proteinuria remains to be seen, but if it does, then
elevated plasma fibrinogen concentrations found in patients with
only mild proteinuria can be interpreted as an indication that net
renal albumin loss is greater than indicated by the proteinuria.
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APPENDIX
Abbreviations used in this article are: ASR, absolute synthesis rate;
GC/C/IRMS, gas chromatography combustion isotope ratio mass spec-
trometry; SAA, serum amyloid A; CRP, C-reactive protein; TCA, trichlo-
ric acetic acid; SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel
electrophoresis; COP, colloid osmotic pressure; FSR, fractional synthesis
rate; FCR, fractional catabolic rate; HDL, high density lipoprotein.
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